INKT MiNK Therapeutics
- 0.969
- +0.017+1.77%
- 1.010
- +0.041+4.19%
MiNK Therapeutics News
Buy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial Moves
MiNK Therapeutics Analyst Ratings
Robert W. Baird Keeps Their Buy Rating on MiNK Therapeutics (INKT)
Analysts Offer Insights on Healthcare Companies: Apyx Medical (APYX) and MiNK Therapeutics (INKT)
MiNK Therapeutics Analyst Ratings
MiNK Therapeutics (INKT) Gets a Buy From H.C. Wainwright
B.Riley Financial Sticks to Their Buy Rating for MiNK Therapeutics (INKT)
H.C. Wainwright Sticks to Its Buy Rating for MiNK Therapeutics (INKT)
Robert W. Baird Reaffirms Their Buy Rating on MiNK Therapeutics (INKT)
HC Wainwright Adjusts MiNK Therapeutics Price Target to $10 From $7, Maintains Buy Rating
B.Riley Financial Keeps Their Buy Rating on MiNK Therapeutics (INKT)
MiNK Therapeutics (INKT) Has a New Rating From H.C. Wainwright
Robert W. Baird Keeps Their Buy Rating on MiNK Therapeutics (INKT)
H.C. Wainwright Keeps Their Buy Rating on MiNK Therapeutics (INKT)
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $7 Price Target
Evercore ISI Adjusts MiNK Therapeutics' Price Target to $3 From $4, Keeps Outperform Rating
Evercore ISI Group Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $3
Analysts' Top Healthcare Picks: X4 Pharmaceuticals (XFOR), MiNK Therapeutics (INKT)
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $7 Price Target
H.C. Wainwright Sticks to Its Buy Rating for MiNK Therapeutics (INKT)
Analysis
Price Target
No Data
